Fortitude Biomedicines

🗓 Founded 2025👥 8 employees💰 Last funded Feb 2026
Biotechnology Research🌐 fortitudebio.com
Website LinkedIn
Fortitude Biomedicines is a private biotechnology company headquartered in Waltham, Massachusetts, pioneering next-generation immune cell targeting biologics and an antibody–drug conjugate (ADC) platform powered by proprietary molecular glue payloads. By integrating the precision targeting of ADCs with the catalytic power of targeted protein degradation, the company is developing transformative therapies with the potential to expand the therapeutic window of ADCs, overcome resistance mechanisms, and unlock new target space. Leveraging a robust discovery engine and an experienced team of drug hunters, Fortitude is building a differentiated pipeline of biologics and ADCs aimed at delivering meaningful benefits to patients with high unmet medical need. Investor Relations and Media Contact IR@fortitudebio.com
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2025
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Hong Kong SAR
1
Frequently asked questions
Who invested in Fortitude Biomedicines?
Fortitude Biomedicines has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Fortitude Biomedicines last raise funding?
The most recent investment in Fortitude Biomedicines recorded on gritt.io was in February 2026.
When was Fortitude Biomedicines founded?
Fortitude Biomedicines was founded in 2025.
What industry is Fortitude Biomedicines in?
Fortitude Biomedicines operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.